Biotech Investment on the Rise (Taiwan)
This article was originally published in PharmAsia News
Taiwan is well on its way to becoming one of the leading biotechnology centers in Asia. International biotechnology firm MediVas LLC has selected Taiwan as the launch point for its entry into the region. MediVas chose Taiwan over competitors like China and India because of strong government backing for the further growth of the biotech and pharmaceutical markets. For example, Taiwan's National Development Fund has recently announced a $20 million investment in TaiMed Biologic's Co., a biotechnology company that recently acquired a patent for a promising new AIDS treatment. For its part, MediVas focuses on improving drug-delivery. Its Taiwan facility is expected to concentrate on using superior delivery methods to create "super-generic" pharmaceuticals. Super-generics are expired-patent drugs that would be re-patented by MediVas using more effective forms of delivery than the original treatment. (Click here for more
You may also be interested in...
The approval is based on the results ABRE clinical study, which showed the stent improved patency iliofemoral veins in 88% of cases with a 2% rate of major adverse events.
Reporting its first full quarter of financials since merging with Allergan, AbbVie will be scrutinized for whether its optimistic talk of a quick Botox rebound actually happened.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.